feed,title,long_url,short_url
Benzinga,EXCLUSIVE: Longeveron's Lomecel-B Cell Therapy Meets Primary Safety Endpoint In Phase 1 Rare Congenital Heart Disease Study,https://benzinga.com/general/biotech/21/09/22859856/exclusive-longeverons-lomecel-b-cell-therapy-meets-primary-safety-endpoint-in-phase-1-rare-congen,https://j.mp/3BVoocx
